Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06277362

Peripheral Extreme Revascularization in "No-option" Patiens With Chronic Limb Threatening Ischemia

The objective of the study is to evaluate early safety and effectiveness of the percutaneous deep foot venous arterialization performed in clinical practice, in an unselected population of patients with "no-option" CLTI.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Critical lower Limb Threatening Ischemia is the most advanced stage of lower limb arterial disease and is associated with a high risk of mortality and major amputation.Literature data indicate that about 5-10% of patients with peripheral arterial disease have a risk of developing CLTI, therefore the most advanced stage of arterial disease of the lower limbs, within 5 years and have a mortality of 20% at 6 months after diagnosis of CLTI.Despite the continuous improvement of the techniques and materials used in the revascularization of these patients, the data of the Literature show that in about 10-15% of these patients revascularization is impossible or ineffective. This condition is defined as: "no-option" CLTI.Therefore, for patients with "no-option" CLTI an alternative treatment for limb rescue may be considered the use of arterialization of the venous plexus of the foot; that is, to use to bring the arterial flow to the foot a healthy conduit, such as the vein, instead of the diseased artery and no longer usable.

The present study is designed as a multicentre, prospective, single-arm, observational study.

All eligible subjects for undergoing PiPER procedure at sites participating in the study will be considered for enrolment and will be asked to give consent prior to participating.

Subjects will be considered enrolled in the study at the time written informed consent is given to the use of their personal data. Once patients are enrolled, their demographics, medical history, disease-relevant conditions, treatment details and outcomes will be collected for up to 24 months from the procedure.

The study will collect information about the medical care patients receive during their planned procedure. No additional testing or procedures will be done.

The revascularization procedure will be performed as per the current clinical practice.

After discharge all patients will attend clinic visits at 30 days (±7 days), 6 months (±14 days),12 months (±30 days), 24 months (±30 days).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Patient has signed an approved informed consent form
  • All patients, with non-revascularizable critical lower limb ischemia defined on the basis of 2 previous unsuccessful Percutaneous Transluminal Angioplasty (PTA) attempts or on severe Medial Artery Calcification (MAC)/Small Artery Disease (SAD) stage.
  • Patient with Critical Limb Ischaemia, Rutherford category, 5 (minor tissue loss) or 6 (major tissue loss) with active trophic lesions
  • Ejection Fraction > 30%

Exclusion criteria

  • Subject no able to perform the follow up or other factors making clinical follow-up difficult
  • Patients with critical ischaemia of the lower limbs revascularizable by bypass or angioplasty, critical ischaemia characterised by rest pain (Rutherford class ≤ 4)
  • Ejection Fraction < 30%

Treatment and study plan

Primary outcomes

  1. Safety Composite

    Time frame: 30 days, 6 months

    Composite of amputation free survival, defined as the rate of limb salvage (freedom from major amputation) and survival (freedom from all causes of death) of the percutaneous deep foot venous arterialization procedure.

Secondary outcomes

  1. Procedural Success

    Time frame: Day 1

    Procedural success (defined as completion of the procedure by percutaneous route with achievement of arterial flow in the venous plexus of the foot at the end, as angiographically assessed);

  2. Primary Patency

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Primary patency defined as no occlusion of the arterialized vein tract

  3. Secondary Patency

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Secondary patency defined as no secondary occlusion of the arterialised vein tract

  4. A-V fistula flow rate

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    A-V fistula flow rate

  5. Minor amputation rates

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Minor amputation rates defined as a below the ankle amputation

  6. Major amputation rates

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Major amputation rates defined as an above the ankle amputation

  7. Re-Treatment rate

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Re-Treatment rate defined as need for reintervention

  8. Wound Size

    Time frame: Baseline, 30 days, 3 months, 6 months, 12 months and 24 months

    Wound Size defined as wound size reduction index

  9. TpcO2

    Time frame: Baseline, 30 days, 3 months, 6 months, 12 months and 24 months

    TpcO2 defined as TpcO2 value changes

  10. WIFi class

    Time frame: Baseline, 30 days, 3 months, 6 months, 12 months and 24 months

    WIFi class and stage changes

  11. Freedom from all cause death

    Time frame: 30 days, 3 months, 6 months, 12 months and 24 months

    Freedom from all cause death

  12. Freedom from procedure-related death

    Time frame: 30 days, 3 months

    Freedom from procedure-related death

  13. Rutherford class

    Time frame: Baseline, 30 days, 3 months, 6 months, 12 months and 24 months

    Rutherford class and stage changes

Study contacts

Contact information is provided by the study sponsor or research team.

Bruno Migliara, MD

CONTACT

[email protected]

Gabriele Morselli, PharmD

CONTACT

[email protected]

+39 3499105666

Sponsors and collaborators

Lead sponsor

EndoCore Lab s.r.l.

Other

Registry information

Official study title

"Arterial-Venous Reversal Flow in "No-option" Chronic Limb-threating Ischemia (CLTI) Patients"

Acronym: PiPER

Important dates

Study start
2020
Primary completion
2028
Study completion
2028
First posted
Feb 26, 2024
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.